Instruction for use: LevodopaI want this, give me price
The Latin name of the substance Levodopa
Levodopum (genus. Levodopi)
The nosological classification (ICD-10)
G20 Parkinson's disease: A trembling paralysis; Idiopathic Parkinsonism; Parkinson's disease; Symptomatic Parkinsonism
G21 Secondary Parkinsonism: Medicinal Parkinsonism; Parkinsonism; Parkinsonism symptomatic; Disorders of extrapyramidal system; Parkinson's Syndrome
Characteristics of substance Levodopa
White crystalline powder. Slightly soluble in water, insoluble in alcohol.
The pharmacological action is antiparkinsonian.
It is a precursor of dopamine. It penetrates through the BBB, accumulates in the basal ganglia and turns into dopamine, replacing the lack of the latter in the extrapyramidal system. As a consequence, muscle stiffness and hypokinesia decrease. Well absorbed when taken orally; Cmax is determined after 1-2 hours, some part of it already in the blood is transformed into dopamine and does not enter the basal nuclei (dopamine does not pass the BBB). It is excreted mainly by the kidneys.
Application of substance Levodopa
Parkinson's disease, symptomatic parkinsonism.
Hypersensitivity, severe atherosclerosis, hypertension, liver, kidney, blood, glaucoma, melanoma, bronchial asthma, mental illness, uncompensated pathology of cardiovascular, respiratory, endocrine systems.
Restrictions on the use
Pregnancy, breastfeeding, children's age (up to 12 years), myocardial infarction in the anamnesis.
Side effects of Levodopa
Choreoathetoid hyperkinesis, arrhythmia, psychotic and paranoid reactions, dyspeptic phenomena, gastrointestinal ulceration, headache, dizziness, visual impairment, hemolytic anemia, agranulocytosis and leukopenia, alopecia, allergic reactions.
The effect weakens vitamin B6. Enhances the effect of MAO inhibitors.
Routes of administration